SOPHiA GENETICS (SOPH) EV/EBITDA: History & Chart

Basis: Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Source: stored company filings and market data; unavailable inputs remain N/A.

The EV/EBITDA ratio is N/A as of 2026-10-06T19:08:17.148Z.

Stored calculation inputs

Calculation as of: 2026-10-06T19:08:17.148Z.

Quote observation: 2026-10-06T19:05:09.000Z. Amounts in USD. The price header may show a later quote.

Quote market capitalization: 619,986,001
Total debt · period ending 2026-06-30: 61,827,000
Cash · period ending 2026-06-30: 107,665,000
TTM operating EBITDA · period ending 2026-06-30: -64,056,000

FMP input reference: bc1f4c18f19876ab16fbc38bb33c2f59d02ebf5b777874ee4386cd5e587f8fe3

EV/Sales|P/E Ratio|EBITDA|All Metrics

SOPH EV/EBITDA Ratio Metrics

EV/EBITDA RATIO

N/A

SOPH Competitors' EV/EBITDA Ratio

SOPH

SOPHiA GENETICS S.A.

Current

Market Cap

$619.99M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

CLYM

Climb Bio, Inc.

vs SOPH

Market Cap

$612.71M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

OABI

OmniAb, Inc.

vs SOPH

Market Cap

$625.56M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

ZVRA

Zevra Therapeutics, Inc.

vs SOPH

Market Cap

$627.39M

EV/EBITDA Ratio

11.94x

TTM Avg

14.05x

3Y Avg

14.05x

5Y Avg

17.93x

AURA

Aura Biosciences, Inc.

vs SOPH

Market Cap

$634.07M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

IRWD

Ironwood Pharmaceuticals, Inc.

vs SOPH

Market Cap

$600.99M

EV/EBITDA Ratio

3.86x

TTM Avg

7.68x

3Y Avg

8.80x

5Y Avg

8.39x

ANGO

AngioDynamics, Inc.

vs SOPH

Market Cap

$596.54M

EV/EBITDA Ratio

N/A

TTM Avg

8.45x

3Y Avg

304.75x

5Y Avg

435.98x

PRME

Prime Medicine, Inc.

vs SOPH

Market Cap

$654.74M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

KIDS

OrthoPediatrics Corp.

vs SOPH

Market Cap

$584.08M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

STLN

Starling Oncology, Inc.

vs SOPH

Market Cap

$658.53M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

NAME	MARKET CAP	EV/EBITDA RATIO	TTM	3Y	5Y
SOPHiA GENETICS S.A. (SOPH)	$619.99M	N/A	N/A	N/A	N/A
Climb Bio, Inc. (CLYM)vs ›	$612.71M	N/A	N/A	N/A	N/A
OmniAb, Inc. (OABI)vs ›	$625.56M	N/A	N/A	N/A	N/A
Zevra Therapeutics, Inc. (ZVRA)vs ›	$627.39M	11.94x	14.05x	14.05x	17.93x
Aura Biosciences, Inc. (AURA)vs ›	$634.07M	N/A	N/A	N/A	N/A
Ironwood Pharmaceuticals, Inc. (IRWD)vs ›	$600.99M	3.86x	7.68x	8.80x	8.39x
AngioDynamics, Inc. (ANGO)vs ›	$596.54M	N/A	8.45x	304.75x	435.98x
Prime Medicine, Inc. (PRME)vs ›	$654.74M	N/A	N/A	N/A	N/A
OrthoPediatrics Corp. (KIDS)vs ›	$584.08M	N/A	N/A	N/A	N/A
Starling Oncology, Inc. (STLN)vs ›	$658.53M	N/A	N/A	N/A	N/A

EV/EBITDA Ratio Formula & Definition

EV/EBITDA = Enterprise Value / EBITDA (TTM)

Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

Related Metrics

EV/Sales P/E Ratio EBITDA All Metrics

EV/EBITDA Ratio: N/A

SOPH EV/EBITDA Ratio Metrics

SOPH Competitors' EV/EBITDA Ratio

EV/EBITDA Ratio Formula & Definition

Related Metrics